Andy Chen
Stock Analyst at Wolfe Research
(4.50)
# 880
Out of 5,182 analysts
46
Total ratings
60%
Success rate
23.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PALI Palisade Bio | Initiates: Outperform | $7 | $1.96 | +257.14% | 1 | Apr 9, 2026 | |
| AVTX Avalo Therapeutics | Initiates: Outperform | $48 | $14.42 | +232.87% | 1 | Apr 9, 2026 | |
| DNTH Dianthus Therapeutics | Initiates: Outperform | $98 | $87.16 | +12.44% | 1 | Apr 9, 2026 | |
| PHVS Pharvaris | Initiates: Outperform | $42 | $28.71 | +46.29% | 1 | Apr 9, 2026 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $12 → $24 | $16.85 | +42.43% | 4 | Mar 23, 2026 | |
| VERA Vera Therapeutics | Upgrades: Outperform | $88 | $37.28 | +136.05% | 3 | Mar 11, 2026 | |
| APGE Apogee Therapeutics | Initiates: Peer Perform | n/a | $86.49 | - | 1 | Jan 7, 2026 | |
| IMVT Immunovant | Upgrades: Outperform | $50 | $28.62 | +74.70% | 3 | Jan 6, 2026 | |
| KYMR Kymera Therapeutics | Downgrades: Peer Perform | n/a | $86.68 | - | 3 | Jan 6, 2026 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $548 | $426.01 | +28.64% | 2 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $783.74 | - | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $13.04 | - | 3 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $40.95 | - | 1 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Peer Perform | n/a | $308.51 | - | 3 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $49 | $74.52 | -34.25% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $20.98 | - | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $66.59 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $38.62 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $76.39 | -73.82% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $18.59 | +2.21% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $95.72 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $33.66 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $520.09 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.50 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $72.23 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $50.99 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $27.85 | -38.96% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $135.98 | -69.11% | 1 | Feb 15, 2024 |
Palisade Bio
Apr 9, 2026
Initiates: Outperform
Price Target: $7
Current: $1.96
Upside: +257.14%
Avalo Therapeutics
Apr 9, 2026
Initiates: Outperform
Price Target: $48
Current: $14.42
Upside: +232.87%
Dianthus Therapeutics
Apr 9, 2026
Initiates: Outperform
Price Target: $98
Current: $87.16
Upside: +12.44%
Pharvaris
Apr 9, 2026
Initiates: Outperform
Price Target: $42
Current: $28.71
Upside: +46.29%
MoonLake Immunotherapeutics
Mar 23, 2026
Upgrades: Outperform
Price Target: $12 → $24
Current: $16.85
Upside: +42.43%
Vera Therapeutics
Mar 11, 2026
Upgrades: Outperform
Price Target: $88
Current: $37.28
Upside: +136.05%
Apogee Therapeutics
Jan 7, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $86.49
Upside: -
Immunovant
Jan 6, 2026
Upgrades: Outperform
Price Target: $50
Current: $28.62
Upside: +74.70%
Kymera Therapeutics
Jan 6, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $86.68
Upside: -
Vertex Pharmaceuticals
Jan 6, 2026
Upgrades: Outperform
Price Target: $548
Current: $426.01
Upside: +28.64%
Nov 24, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $783.74
Upside: -
Nov 12, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $13.04
Upside: -
Nov 6, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $40.95
Upside: -
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $308.51
Upside: -
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $74.52
Upside: -34.25%
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $20.98
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $66.59
Upside: -
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $38.62
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $76.39
Upside: -73.82%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $18.59
Upside: +2.21%
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $95.72
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $33.66
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $520.09
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $13.50
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $72.23
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $50.99
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $27.85
Upside: -38.96%
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $135.98
Upside: -69.11%